JP6214643B2 - ピリミジニルチロシンキナーゼ阻害剤 - Google Patents
ピリミジニルチロシンキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP6214643B2 JP6214643B2 JP2015516256A JP2015516256A JP6214643B2 JP 6214643 B2 JP6214643 B2 JP 6214643B2 JP 2015516256 A JP2015516256 A JP 2015516256A JP 2015516256 A JP2015516256 A JP 2015516256A JP 6214643 B2 JP6214643 B2 JP 6214643B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- acceptable salt
- pharmaceutically acceptable
- amino
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*C([C@@](CCN(C1)c(ncnc2N)c2F)[C@]1N(CCC[C@]1Nc2cc(Cl)cc(*)c2)C1=O)=O Chemical compound C*C([C@@](CCN(C1)c(ncnc2N)c2F)[C@]1N(CCC[C@]1Nc2cc(Cl)cc(*)c2)C1=O)=O 0.000 description 6
- NNHLHUQUOSCOEN-YSTUSHMSSA-N CN(CC1)CCN1C([C@@H](CCN(C1)c2ncnc(N)c2F)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O Chemical compound CN(CC1)CCN1C([C@@H](CCN(C1)c2ncnc(N)c2F)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O NNHLHUQUOSCOEN-YSTUSHMSSA-N 0.000 description 1
- XIXPQPAHEZDFNG-WMEOFMBSSA-N CN(CC1)CCN1C([C@@H](CCNC1)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O Chemical compound CN(CC1)CCN1C([C@@H](CCNC1)[C@H]1N(CCCC1Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O)=O XIXPQPAHEZDFNG-WMEOFMBSSA-N 0.000 description 1
- GUPKEOUZKHLRGS-HYPNFROTSA-N C[C@@H](c1ccccc1)/N=C(\CN(CC1)c(ncnc2N)c2F)/C1C(O)=O Chemical compound C[C@@H](c1ccccc1)/N=C(\CN(CC1)c(ncnc2N)c2F)/C1C(O)=O GUPKEOUZKHLRGS-HYPNFROTSA-N 0.000 description 1
- SUMCMXORPZCWHU-UHFFFAOYSA-N NC(C1F)=NC=NC1Cl Chemical compound NC(C1F)=NC=NC1Cl SUMCMXORPZCWHU-UHFFFAOYSA-N 0.000 description 1
- OVENUGPMQDFGLE-UHFFFAOYSA-N Nc1cc(Cl)cc(C(F)(F)F)c1 Chemical compound Nc1cc(Cl)cc(C(F)(F)F)c1 OVENUGPMQDFGLE-UHFFFAOYSA-N 0.000 description 1
- FEIFDRDCVMVUJA-UHFFFAOYSA-N Nc1ncnc(Cl)c1F Chemical compound Nc1ncnc(Cl)c1F FEIFDRDCVMVUJA-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261657360P | 2012-06-08 | 2012-06-08 | |
| US61/657,360 | 2012-06-08 | ||
| PCT/US2013/044800 WO2013185084A1 (en) | 2012-06-08 | 2013-06-07 | Pyrimidinyl tyrosine kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150480A Division JP2017193583A (ja) | 2012-06-08 | 2017-08-03 | ピリミジニルチロシンキナーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015518903A JP2015518903A (ja) | 2015-07-06 |
| JP2015518903A5 JP2015518903A5 (OSRAM) | 2016-07-28 |
| JP6214643B2 true JP6214643B2 (ja) | 2017-10-18 |
Family
ID=49712704
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516256A Expired - Fee Related JP6214643B2 (ja) | 2012-06-08 | 2013-06-07 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2017150480A Withdrawn JP2017193583A (ja) | 2012-06-08 | 2017-08-03 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2019017850A Withdrawn JP2019077728A (ja) | 2012-06-08 | 2019-02-04 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018128A Pending JP2021073299A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018127A Pending JP2021073298A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2023004462A Pending JP2023052415A (ja) | 2012-06-08 | 2023-01-16 | ピリミジニルチロシンキナーゼ阻害剤 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017150480A Withdrawn JP2017193583A (ja) | 2012-06-08 | 2017-08-03 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2019017850A Withdrawn JP2019077728A (ja) | 2012-06-08 | 2019-02-04 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018128A Pending JP2021073299A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2021018127A Pending JP2021073298A (ja) | 2012-06-08 | 2021-02-08 | ピリミジニルチロシンキナーゼ阻害剤 |
| JP2023004462A Pending JP2023052415A (ja) | 2012-06-08 | 2023-01-16 | ピリミジニルチロシンキナーゼ阻害剤 |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9394277B2 (OSRAM) |
| EP (3) | EP2858499B1 (OSRAM) |
| JP (6) | JP6214643B2 (OSRAM) |
| KR (4) | KR20200043497A (OSRAM) |
| CN (3) | CN104540385B (OSRAM) |
| AR (1) | AR091273A1 (OSRAM) |
| AU (5) | AU2013271407B2 (OSRAM) |
| BR (2) | BR122021002178B1 (OSRAM) |
| CA (2) | CA3108186A1 (OSRAM) |
| CY (1) | CY1120638T1 (OSRAM) |
| DK (1) | DK2858499T3 (OSRAM) |
| EA (2) | EA027823B1 (OSRAM) |
| ES (2) | ES2684268T3 (OSRAM) |
| HR (1) | HRP20181294T1 (OSRAM) |
| HU (1) | HUE039897T2 (OSRAM) |
| IL (2) | IL235938B (OSRAM) |
| IN (1) | IN2014DN10576A (OSRAM) |
| LT (1) | LT2858499T (OSRAM) |
| MX (2) | MX385593B (OSRAM) |
| NZ (1) | NZ702715A (OSRAM) |
| PH (2) | PH12018501463B1 (OSRAM) |
| PL (1) | PL2858499T3 (OSRAM) |
| PT (1) | PT2858499T (OSRAM) |
| RS (1) | RS57978B1 (OSRAM) |
| SG (2) | SG10201708535UA (OSRAM) |
| SI (1) | SI2858499T1 (OSRAM) |
| SM (1) | SMT201800442T1 (OSRAM) |
| TW (3) | TWI719209B (OSRAM) |
| WO (1) | WO2013185084A1 (OSRAM) |
| ZA (1) | ZA201409255B (OSRAM) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2473049T3 (en) | 2009-09-04 | 2019-04-01 | Biogen Ma Inc | INHIBITORS OF BRUTON'S TYROSINKINASE |
| US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| DK3080103T3 (en) * | 2013-12-11 | 2018-07-30 | Biogen Ma Inc | BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| CA2965517C (en) | 2014-10-24 | 2023-05-02 | Bristol-Myers Squibb Company | Indole carboxamides compounds useful as kinase inhibitors |
| AU2017298035B2 (en) | 2016-07-21 | 2021-10-28 | Biogen Ma Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
| EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
| KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240216330A1 (en) | 2021-04-02 | 2024-07-04 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| WO2023081715A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| WO2023081709A1 (en) | 2021-11-03 | 2023-05-11 | Viracta Therapeutics, Inc. | Vecabrutinib for the treatment of graft-versus-host disease |
| AU2022409472A1 (en) | 2021-12-14 | 2024-06-27 | Crossfire Oncology Holding B.V. | Macrocyclic btk inhibitors |
| WO2024246287A1 (en) | 2023-06-02 | 2024-12-05 | Crossfire Oncology Holding B.V. | Medical use of a macrocyclic reversible btk inhibitor |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
| WO2024256568A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Salt and crystal forms of a macrocyclic btk inhibitor |
| WO2024256574A1 (en) | 2023-06-13 | 2024-12-19 | Crossfire Oncology Holding B.V. | Process for preparing macrocyclic btk inhibitors |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1624A (en) * | 1840-06-10 | Cooking-stove | ||
| US4528138A (en) | 1984-06-20 | 1985-07-09 | E. R. Squibb & Sons, Inc. | 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| ATE141502T1 (de) | 1991-01-15 | 1996-09-15 | Alcon Lab Inc | Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| US6919178B2 (en) | 2000-11-21 | 2005-07-19 | Sunesis Pharmaceuticals, Inc. | Extended tethering approach for rapid identification of ligands |
| WO2001070673A2 (en) | 2000-03-17 | 2001-09-27 | Bristol-Myers Squibb Pharma Company | CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| MY137020A (en) | 2000-04-27 | 2008-12-31 | Abbott Lab | Diazabicyclic central nervous system active agents |
| JP4068958B2 (ja) | 2000-06-26 | 2008-03-26 | ファイザー・プロダクツ・インク | 免疫抑制剤としてのピロロ（２，３−ｄ）ピリミジン化合物 |
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
| CA2464934A1 (en) | 2001-10-31 | 2003-05-08 | Bayer Healthcare Ag | Pyrimido [4,5-b] indole derivatives |
| EP1599468B1 (en) | 2003-01-14 | 2007-10-03 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
| ES2344007T3 (es) | 2003-10-14 | 2010-08-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Inhibidores proteina quinasa. |
| US20080253960A1 (en) * | 2004-04-01 | 2008-10-16 | The Trustees Of The University Of Pennsylvania Center For Technology Transfer | Lipoprotein-Based Nanoplatforms |
| CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| TW200621760A (en) | 2004-09-09 | 2006-07-01 | Mitsubishi Pharma Corp | 2-morpholino-4-pyrimidone compound |
| KR20070090172A (ko) * | 2004-11-04 | 2007-09-05 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘 |
| JP5254620B2 (ja) | 2004-12-03 | 2013-08-07 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｃｂ１アンタゴニストとしての置換ピペラジン |
| EP1848719B1 (en) | 2004-12-28 | 2012-02-01 | Exelixis, Inc. | [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| US7423043B2 (en) * | 2005-02-18 | 2008-09-09 | Lexicon Pharmaceuticals, Inc. | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds |
| US20060281764A1 (en) | 2005-06-10 | 2006-12-14 | Gaul Michael D | Aminopyrimidines as kinase modulators |
| US20060281700A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators |
| TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
| KR101467723B1 (ko) | 2005-11-01 | 2014-12-03 | 탈자진 인코포레이티드 | 키나제의 비-아릴 메타-피리미딘 억제제 |
| EP1965862A2 (en) * | 2005-12-21 | 2008-09-10 | Schering Corporation | Combination of an h3 antagonist/inverse agonist and an appetite suppressant |
| US20080076924A1 (en) | 2006-06-30 | 2008-03-27 | Patrick Betschmann | Piperazines as P2X7 antagonists |
| WO2008012635A2 (en) | 2006-07-26 | 2008-01-31 | Pfizer Products Inc. | Amine derivatives useful as anticancer agents |
| US20090325948A1 (en) | 2006-07-26 | 2009-12-31 | Timothy Brian Hurley | Inhibitors of undecaprenyl pyrophosphate synthase |
| US20100160292A1 (en) | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
| PL2526933T3 (pl) * | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| CA2679807A1 (en) * | 2007-03-02 | 2008-09-12 | Schering Corporation | Piperidine derivatives and methods of use thereof |
| WO2008116064A2 (en) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| WO2008144253A1 (en) | 2007-05-14 | 2008-11-27 | Irm Llc | Protein kinase inhibitors and methods for using thereof |
| CN101932580B (zh) | 2007-06-01 | 2013-05-22 | 葛兰素史密丝克莱恩有限责任公司 | 咪唑并吡啶激酶抑制剂 |
| HRP20130615T1 (en) | 2008-02-05 | 2013-08-31 | F. Hoffmann - La Roche Ag | Novel pyridinones and pyridazinones |
| US8617823B2 (en) | 2008-04-29 | 2013-12-31 | Immunexcite, Inc. | Immunomodulating compositions and methods of use thereof |
| ES2660418T3 (es) * | 2008-07-16 | 2018-03-22 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton para el tratamiento de tumores sólidos |
| WO2010068788A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
| SG171815A1 (en) * | 2008-12-19 | 2011-07-28 | Bristol Myers Squibb Co | Carbazole carboxamide compounds useful as kinase inhibitors |
| WO2010080712A2 (en) * | 2009-01-06 | 2010-07-15 | Dana Farber Cancer Institute | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| WO2010136422A1 (de) | 2009-05-25 | 2010-12-02 | Sandoz Ag | Verfahren zur herstellung von ceftobiprol medocaril |
| DK2473049T3 (en) | 2009-09-04 | 2019-04-01 | Biogen Ma Inc | INHIBITORS OF BRUTON'S TYROSINKINASE |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| US8685880B2 (en) | 2010-06-30 | 2014-04-01 | Chevron U.S.A. Inc. | On-site drying of aqueous salt for ionic liquid make-up |
| US9273028B2 (en) | 2010-10-29 | 2016-03-01 | Biogen Ma Inc. | Heterocyclic tyrosine kinase inhibitors |
| WO2013185082A2 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Inhibitors of bruton's tyrosine kinase |
| AR091273A1 (es) | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| DK3080103T3 (en) | 2013-12-11 | 2018-07-30 | Biogen Ma Inc | BIARYL COMPOUNDS USED FOR TREATING HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY |
| US10280169B2 (en) | 2013-12-11 | 2019-05-07 | Biogen Ma Inc. | Biaryl bruton's tyrosine kinase inhibitors |
| WO2016054627A1 (en) | 2014-10-03 | 2016-04-07 | Ohio State Innovation Foundation | Biomarkers of bruton tyrosine kinase inhibitor resistance |
| AU2017298035B2 (en) * | 2016-07-21 | 2021-10-28 | Biogen Ma Inc. | Succinate forms and compositions of Bruton's tyrosine kinase inhibitors |
-
2013
- 2013-06-05 AR ARP130101980 patent/AR091273A1/es not_active Application Discontinuation
- 2013-06-07 BR BR122021002178-3A patent/BR122021002178B1/pt active IP Right Grant
- 2013-06-07 KR KR1020207010675A patent/KR20200043497A/ko not_active Ceased
- 2013-06-07 KR KR1020227039393A patent/KR20220154850A/ko not_active Ceased
- 2013-06-07 JP JP2015516256A patent/JP6214643B2/ja not_active Expired - Fee Related
- 2013-06-07 MX MX2019003618A patent/MX385593B/es unknown
- 2013-06-07 IN IN10576DEN2014 patent/IN2014DN10576A/en unknown
- 2013-06-07 ES ES13800042.7T patent/ES2684268T3/es active Active
- 2013-06-07 CN CN201380036869.5A patent/CN104540385B/zh not_active Expired - Fee Related
- 2013-06-07 WO PCT/US2013/044800 patent/WO2013185084A1/en not_active Ceased
- 2013-06-07 NZ NZ702715A patent/NZ702715A/en not_active IP Right Cessation
- 2013-06-07 EA EA201492056A patent/EA027823B1/ru unknown
- 2013-06-07 BR BR112014030655-9A patent/BR112014030655B1/pt not_active IP Right Cessation
- 2013-06-07 TW TW106116775A patent/TWI719209B/zh not_active IP Right Cessation
- 2013-06-07 CN CN201810384098.3A patent/CN109305959B/zh active Active
- 2013-06-07 DK DK13800042.7T patent/DK2858499T3/en active
- 2013-06-07 SI SI201331130T patent/SI2858499T1/sl unknown
- 2013-06-07 HU HUE13800042A patent/HUE039897T2/hu unknown
- 2013-06-07 ES ES18171833T patent/ES2834333T3/es active Active
- 2013-06-07 KR KR1020217017552A patent/KR102468430B1/ko active Active
- 2013-06-07 AU AU2013271407A patent/AU2013271407B2/en not_active Ceased
- 2013-06-07 EP EP13800042.7A patent/EP2858499B1/en active Active
- 2013-06-07 CA CA3108186A patent/CA3108186A1/en not_active Abandoned
- 2013-06-07 US US14/406,315 patent/US9394277B2/en active Active
- 2013-06-07 HR HRP20181294TT patent/HRP20181294T1/hr unknown
- 2013-06-07 CN CN202110783143.4A patent/CN113549055A/zh active Pending
- 2013-06-07 PT PT13800042T patent/PT2858499T/pt unknown
- 2013-06-07 PH PH1/2018/501463A patent/PH12018501463B1/en unknown
- 2013-06-07 SG SG10201708535UA patent/SG10201708535UA/en unknown
- 2013-06-07 TW TW102120447A patent/TWI592406B/zh not_active IP Right Cessation
- 2013-06-07 TW TW110102365A patent/TWI792158B/zh not_active IP Right Cessation
- 2013-06-07 PL PL13800042T patent/PL2858499T3/pl unknown
- 2013-06-07 SG SG11201408173WA patent/SG11201408173WA/en unknown
- 2013-06-07 MX MX2014015044A patent/MX363672B/es unknown
- 2013-06-07 EA EA201790418A patent/EA201790418A1/ru unknown
- 2013-06-07 CA CA2875799A patent/CA2875799C/en active Active
- 2013-06-07 EP EP20186539.1A patent/EP3753934A1/en not_active Withdrawn
- 2013-06-07 LT LTEP13800042.7T patent/LT2858499T/lt unknown
- 2013-06-07 RS RS20180950A patent/RS57978B1/sr unknown
- 2013-06-07 EP EP18171833.9A patent/EP3385263B1/en not_active Not-in-force
- 2013-06-07 KR KR1020157000393A patent/KR102102587B1/ko not_active Expired - Fee Related
- 2013-06-08 SM SM20180442T patent/SMT201800442T1/it unknown
-
2014
- 2014-11-27 IL IL235938A patent/IL235938B/en active IP Right Grant
- 2014-12-03 PH PH12014502699A patent/PH12014502699A1/en unknown
- 2014-12-15 ZA ZA2014/09255A patent/ZA201409255B/en unknown
-
2016
- 2016-06-29 US US15/196,389 patent/US9944622B2/en active Active
-
2017
- 2017-03-07 AU AU2017201536A patent/AU2017201536B2/en not_active Ceased
- 2017-08-03 JP JP2017150480A patent/JP2017193583A/ja not_active Withdrawn
-
2018
- 2018-03-05 US US15/911,546 patent/US10618887B2/en active Active
- 2018-08-16 CY CY181100861T patent/CY1120638T1/el unknown
-
2019
- 2019-02-04 JP JP2019017850A patent/JP2019077728A/ja not_active Withdrawn
- 2019-05-17 AU AU2019203476A patent/AU2019203476B2/en not_active Ceased
-
2020
- 2020-02-27 US US16/802,959 patent/US20210017155A1/en not_active Abandoned
- 2020-10-11 IL IL277951A patent/IL277951A/en unknown
-
2021
- 2021-02-08 JP JP2021018128A patent/JP2021073299A/ja active Pending
- 2021-02-08 JP JP2021018127A patent/JP2021073298A/ja active Pending
- 2021-04-21 AU AU2021202412A patent/AU2021202412A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,202 patent/US20230174511A1/en not_active Abandoned
- 2022-11-25 AU AU2022275504A patent/AU2022275504A1/en not_active Abandoned
-
2023
- 2023-01-16 JP JP2023004462A patent/JP2023052415A/ja active Pending
-
2024
- 2024-08-23 US US18/813,750 patent/US20240417389A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6214643B2 (ja) | ピリミジニルチロシンキナーゼ阻害剤 | |
| HK40043767A (en) | Pyrimidinyl derivatives useful as tyrosine kinase inhibitors | |
| HK1262106B (en) | Pyrimidinyl tyrosine kinase inhibitors | |
| HK1262106A1 (en) | Pyrimidinyl tyrosine kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160606 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160606 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170209 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170501 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170824 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170919 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6214643 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |